May. 18 at 12:13 PM
$IBRX I assume this will be mentioned in40 mins during caparison data presentation:
$JNJ TAR-200: The durability drops off a bit quicker over time compared to Anktiva, tracking closer to a
$46% CR rate at 12 months and
$42% at 24 months. It requires placing and later retrieving a physical drug-delivery system from the bladder via a cystoscopic office procedure every few weeks.
Anktiva is a straightforward intravesical instillation (catheter fluid), but it must be administered alongside BCG.
If a urologist has a stable supply of BCG, Anktiva + BCG is highly favored for long-term, multi-year disease-free survival and true bladder preservation.
So they are solving the BCG shortage problem at least 2 ways and will become the SOC!
Thanks for nothing
$MRK !
